ArticleFrontiers in immunology2026

Type-II-CD20-targeted therapy for CD38 antibody-refractory antibody-mediated rejection after kidney transplantation: a case report.

Jonathan de Fallois et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.